Advertisement


James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.



Related Videos

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging...

Immunotherapy

Ann W. Silk, MD, and Katy K. Tsai, MD: Meeting Highlights

Ann W. Silk, MD, of the Rutgers Cancer Institute of New Jersey, and Katy K. Tsai, MD, of the University of California, San Francisco, who are Co-Chairs of the Clin...

Leukemia
Immunotherapy

Kristen Fousek, PhD Candidate, on B-Cell ALL: CAR T-Cell Treatment

Kristen Fousek, PhD Candidate at Baylor College of Medicine, discusses her preclinical work on targeting CD19-negative relapsed B-cell acute lymphoblastic leukemia, using CAR T cel...

Issues in Oncology
Immunotherapy

Aaron Goodman, MD, on Immune Checkpoint Blockade: Clinical Implications

Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification an...

Hematologic Malignancies
Immunotherapy

Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.

Advertisement

Advertisement



Advertisement